What is Reliefband Technologies?
Reliefband Technologies specializes in the development of FDA-cleared, wearable devices that utilize targeted nerve stimulation to mitigate nausea and vomiting. By leveraging patented neuromodulation techniques, the company provides a drug-free alternative for patients suffering from motion sickness, morning sickness, chemotherapy-induced nausea, and migraine-related symptoms. Unlike pharmaceutical interventions that often carry systemic side effects, Reliefband's hardware-centric approach offers a localized, rapid-response therapeutic mechanism. The company maintains a strong footprint in both consumer health and clinical settings, positioning itself as a leader in the intersection of digital health and bioelectronic medicine. Their commitment to safety and efficacy has allowed them to bridge the gap between specialized medical equipment and accessible, patient-centric wearable technology.
How much funding has Reliefband Technologies raised?
Reliefband Technologies has raised a total of $7.8M across 3 funding rounds:
Private Equity
$1.8M
Private Equity
$5M
Debt
$1M
Private Equity (2015): $1.8M, investors not publicly disclosed
Private Equity (2015): $5M, investors not publicly disclosed
Debt (2017): $999K, investors not publicly disclosed
Key Investors in Reliefband Technologies
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Reliefband Technologies?
With the recent capital deployment, Reliefband Technologies is well-positioned to accelerate its market penetration and expand its clinical research initiatives. The strategic focus will likely shift toward broadening the application of its neuromodulation technology to address a wider spectrum of autonomic nervous system conditions. As the company scales, it faces the dual challenge of maintaining rigorous clinical standards while navigating the competitive landscape of the global health-tech market. Future growth will be predicated on the successful integration of its devices into standard-of-care protocols for oncology and prenatal health, alongside potential expansion into new therapeutic verticals that benefit from non-invasive nerve stimulation. The firm's ability to leverage its existing intellectual property portfolio will be critical in sustaining its competitive advantage as it transitions into a more mature phase of enterprise-level operations.
See full Reliefband Technologies company page
